BD Pharmingen™ APO-BRDU™ Kit
1/4

BD Pharmingen™ APO-BRDU™ Kit

分享
品牌: BD Pharmingen
pdf 下载产品说明书
用小程序,查商品更便捷
收藏
对比对比
咨询咨询
    实验应用:
    Flow cytometry, Intracellular staining (flow cytometry) (Tested During Development)
    Flow cytometry, Intracellular staining (flow cytometry) (Tested During Development)
    产品介绍
    产品信息
    抗原名称
    BrdU
    简单描述
    One of the later steps in apoptosis is DNA fragmentation, a process which results from the activation of endonucleases during the apoptotic program. These nucleases degrade the higher order chromatin structure into fragments of ~300 kb and subsequently into smaller DNA pieces of about 50 bp length. A method which is often used to detect fragmented DNA utilizes a reaction catalyzed by exogenous TdT, often referred to as "end-labeling" or "TUNEL" (terminal deoxynucleotidyltransferase dUTP nick end labeling). In the APO-BRDU™ assay, TdT catalyzes a template-independent addition of bromolated deoxyuridine triphosphates (Br-dUTP) to the 3'-hydroxyl (OH) termini of double- and single-stranded DNA. After incorporation, these sites are identified by flow cytometric means by staining the cells with a FITC-labeled anti-BrdU mAb. The APO-DIRECT™ assay (Cat. No. 51-6536KK) is a single-step method for labeling DNA breaks with FITC-dUTP, followed by flow cytometric analysis. The APO-BRDU™ Kit is a two color staining method for labeling DNA breaks and total cellular DNA to detect apoptotic cells by flow cytometry. Sufficient reagents are provided to process 60 cell suspensions. The kit includes 5 ml of positive and 5 ml of negative control cell suspensions, approximately 1 x 10^6 cells per ml in 70% (v/v) ethanol. The control cells are derived from a human lymphoma cell line and have been fixed as described in the Fixation Protocol. The APO-BRDU™ Kit consists of two parts (part A and B).   Part A (Comp. No. 51-6576AK) consists of:   One 0.30 ml bottle of FITC-Labeled Anti-BrdU mAb [Isotype: mouse; 1 µg/test (contains 0.05% sodium azide)] (Comp. No. 51-6584AZ] One 30 ml bottle of PI/RNase Staining Buffer (5 µg/ml, 200 µg/ml RNase) [Comp. No. 51-6585AZ] One 0.6 ml vial of Reaction Buffer (containing cacodylic acid (dimethylarsenic)) [Comp. No. 51-6580AZ ] One 126 ml bottle of Rinsing Buffer (containing 0.05% sodium azide) [Comp. No. 51-6583AZ] One 120 ml botle of Wash Buffer (containing 0.05% sodium azide) [Comp. No. 51-6579AZ].   Part B (Comp. No. 51-6576BK) consists of:   One 0.48 ml bottle of Br-dUTP (54.7 µg/ml)  [Comp. No. 51-6582EZ] One 5 ml bottle of Negative Control Cells [contains 70% (v/v) ethanol] [Comp. No. 51-6578LZ] One 5 ml bottle of Positive Control Cells [contains 70% (v/v) ethanol] [Comp. No. 51-6577LZ} One 0.045 ml bottle of TdT Enzyme [200 µg/ml (S.A.= 100,000 U/mg) in 50% (v/v) glycerol solution; will not freeze at -20°C] [Comp. No. 51-6581EZ]
    克隆号
    (RUO)
    组合货号
    51-6576AK/(2 to 8C)+51-6576BK/(max.-20C)
    BD化合物表
    • 描述
      数量/尺寸
      零件号
      EntrezGene ID
    • APO-BRDU™ Kit Part A
      N/A
      51-6576AK
      N/A
    • APO-BRDU™ Kit Part B
      N/A
      51-6576BK
      N/A
    应用
    实验应用
    Flow cytometry, Intracellular staining (flow cytometry) (Tested During Development)
    目标/特异性
    BrdU

    参考图片

    Schematic Representation of APO-BRDU™ Labeling. The enzyme deoxynucleotidyl transferase (TdT) catalyzes a template dependent addition of bromolated deoxyuridine triphosphates (Br-dUTP) to the 3'-hydroxyl ends of double- and single-stranded DNA. After Br-dUTP incorporation, DNA break sites are identified by a FITC-labeled anti-BrdU mAb.

    Flow Cytometer Setup for Becton Dickinson Hardware. Positive control cells were labeled with both PI (DNA) and FITC-BrdU mAb. Display 1: Non-clumped cells are gated. Gated From Display 1: Separate boxes are drawn around cells that stain positive (upper box) and negative (lower box) with the FITC-BrdU mAb. An example of FACScan™ gain settings is shown.

    Flow Cytometry Data of APO-BRDU™ Negative and Positive Control cells (top row). Negative and Positive control cells were incubated with Br-dUTP in the presence of TdT enzyme in order to incorporate Br-dUTP into exposed 3'-OH DNA ends. Br-dUTP sites are detected with a FITC-labeled anti-BrdU mAb. Non-apoptotic cells do not incorporate significant amounts of Br-dUTP due to the lack of exposed 3'-OH ends, and consequently have relatively little fluorescence compared to apoptotic cells which have an abundance of 3'-OH ends. Flow Cytometric Analysis of HPB-ALL Human Leukemia Cells Using APO-BRDU™ (bottom row). HPB-ALL human leukemia cells were left untreated (left panel) or treated with anti-human Fas mAb, clone DX2 (Cat. No. 33450D) and Protein G for 2 hr (middle panel) or 12 hr (right panel). Cells were fixed and incubated with Br-dUTP in the presence of TdT enzyme in order to incorporate Br-dUTP into exposed 3'-OH DNA ends. Br-dUTP was detected with a FITC-labeled anti-BrdU mAb. Non-apoptotic cells (M1 gates) do not incorporate significant amounts of Br-dUTP due to lack of exposed 3'-OH ends, and consequently have relatively little fluorescence compared to apoptotic cells which have an abundance of 3'-OH end (M2 gates). DX2-induced, Fas-mediated apoptosis is shown by increases in the number of cells staining with anti-BrdU-FITC mAb (M2 gates) after 2 and 12 hr. The M1 and M2 gates demarcate non-apoptotic and apoptotic populations, respectively.

    声明 :本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。
    货号:
    556405
    一键复制
    询价
    60 tests
    选择数量
    当前规格1件起购 
    配送至
    预计3-4周送达,快递: 免运费,若需干冰额外收费